Showing 501 - 520 results of 115,955 for search '(( a non decrease ) OR ( 5 ((wt decrease) OR (((mean decrease) OR (a decrease)))) ))', query time: 1.66s Refine Results
  1. 501
  2. 502
  3. 503
  4. 504
  5. 505

    p35 siRNA knockdown decreased Cdk5 activity, diminished WT1 expression and viable cell numbers, but did not affect a cell apoptosis marker as detected by WB. by Ya-Li Zheng (454837)

    Published 2016
    “…C. p35 siRNA reduced Cdk5 activity. D. Western blotting analysis showed a decline of WT1 expression in p35 siRNA podocytes (upper panel, lane 2 compared to lane 1, p = 0,048), but did not affect cleaved caspase 3 expression (middle panel, lane 2 compare with lane 1). …”
  6. 506
  7. 507
  8. 508

    Decreased innervation and decreased epidermal thickness in STZ diabetic rats. by Shoista Kambiz (740608)

    Published 2015
    “…<p>Decreased density PGP9.5-IR nerve fibers (<b>A</b>) and average epidermal thickness (<b>F</b>) was demonstrated in the plantar skin of diabetic animals 4, 6, and 8 weeks after induction of diabetes (black bars) when compared to control (white bar). …”
  9. 509
  10. 510
  11. 511
  12. 512
  13. 513
  14. 514
  15. 515
  16. 516

    Different response of visASCs to a micro-local oxygen concentration decrease in metabolically active sites of the adipose tissue. by Wilfredo Oliva-Olivera (301968)

    Published 2017
    “…However, hypox-visASCs from MS patients show a lower ability to actively participate in or stimulate the formation of microvascular structures, while they favor the accumulation of CD11C<sup>+</sup> and CD163<sup>+</sup> macrophages in the adipose tissue through their contribution to the increased tissue levels of MCP1. ↑ Increased response; <b>↓</b> Decreased response; → Hypox-visASCs main response NonMS: obese subjects without metabolic syndrome; MS: obese subjects with metabolic syndrome; visASC: visceral adipose tissue-derived multipotent mesenchymal cells; hypox-visASCs: visASC under hypoxia; NOX5: NADPH Oxidase 5; SDF1α: stromal cell-derived factor 1α; VEGF: vascular endothelial growth factor; MCP1: monocyte chemoattractant protein 1; CD11C<sup>+</sup>, CD163<sup>+</sup>: proinflammatory macrophage cell-surface markers.…”
  17. 517
  18. 518
  19. 519
  20. 520